IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Vaccines made from tumor antigens may help the body build an effective immune response to kill tumor cells. Biological therapies, such as OPT-821, may stimulate the immune system in different ways and stop tumor cells from growing. Giving vaccine therapy together with OPT-821 may kill more tumor cells. It is not yet known whether giving vaccine therapy together with OPT-821 is more effective than OPT-821 alone in treating ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.
PURPOSE: This randomized phase III trial is studying vaccine therapy and OPT-821 to see how well they work compared with OPT-821 alone in treating patients with ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer in complete remission.
| Condition | Intervention | Phase |
|---|---|---|
| Fallopian Tube Cancer Ovarian Cancer Primary Peritoneal Cavity Cancer | Biological: immunological adjuvant OPT-821 Biological: polyvalent antigen-KLH conjugate vaccine | Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Primary Purpose: Treatment |
| Official Title: | A Randomized Phase III Trial in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer With a Polyvalent Vaccine-KLH Conjugate + OPT-821 Versus OPT-821 |
- Progression-free survival
- Incidence of toxicities
- Overall survival
- Correlation of outcome with antigen-specific immune titers in a limited sampling of patients
| Enrollment: | 0 |
| Study Start Date: | August 2008 |
| Estimated Primary Completion Date: | January 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Arm I
Patients receive polyvalent antigen-KLH conjugate vaccine in combination with OPT-821 subcutaneously (SC) once in weeks 1, 2, 3, 7, 15, 27, 39, 51, 63, 75, and 87.
|
Biological: immunological adjuvant OPT-821
Given subcutaneously
Biological: polyvalent antigen-KLH conjugate vaccine
Given subcutaneously
|
|
Experimental: Arm II
Patients receive OPT-821 SC once in weeks 1, 2, 3, 7, 15, 27, 39, 51, 63, 75, and 87.
|
Biological: immunological adjuvant OPT-821
Given subcutaneously
|
Detailed Description:
OBJECTIVES:
Primary
- To compare the progression-free survival of patients with ovarian epithelial, fallopian tube, or primary peritoneal cancer in second or third complete clinical remission treated with a polyvalent antigen-KLH conjugate vaccine (GM2-KLH, Globo-H-KLH, Tn-MUC1-32mer-KLH, TF-KLH, and sTn-KLH) in combination with OPT-821 vs OPT-821 alone.
Secondary
- To compare the incidence of toxicities in patients treated with these regimens.
- To compare the overall survival of patients treated with these regimens.
- To characterize the immune response (by ELISA) in a limited sampling of patients, in order to determine if the outcome correlates with antigen-specific immune titers.
OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive polyvalent antigen-KLH conjugate vaccine in combination with OPT-821 subcutaneously (SC) once in weeks 1, 2, 3, 7, 15, 27, 39, 51, 63, 75, and 87.
- Arm II: Patients receive OPT-821 SC once in weeks 1, 2, 3, 7, 15, 27, 39, 51, 63, 75, and 87.
Patients undergo blood sample collection periodically for correlative studies. Samples are analyzed for antibody expression to antigens (i.e., Tn-MUC1-32mer, GM2, Globo-H, TF, sTN, and Tn) by ELISA. IgM and IgG titers are also measured.
After completion of study treatment, patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
-
Histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal cancer
- Any stage or grade at diagnosis allowed
-
Has undergone initial cytoreductive surgery or received at least one platinum-based chemotherapy regimen
-
Recurred on initial therapy, but is now in second or third complete clinical remission as defined by the following:
- Serum CA-125 normal
- Negative physical examination
-
No definitive evidence of disease by CT scan of the abdomen and pelvis (lymph nodes and/or soft tissue abnormalities ≤ 1.0 cm are not considered definitive evidence of disease)
- A positive PET scan is allowed provided other criteria are met and MRI or CT scan are negative
- Completed last course of chemotherapy within the past 4 months
-
PATIENT CHARACTERISTICS:
- GOG performance status 0-2
- Absolute neutrophil count ≥ 1,000/mm³
- Platelet count ≥ 100,000/mm³
- Serum creatinine ≤ 1.5 times upper limit of normal (ULN)
- Bilirubin ≤ 2.0 times ULN
- SGOT ≤ 2.0 times ULN
- Alkaline phosphatase ≤ 2.0 times ULN
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00693342
| Study Chair: | Paul Sabbatini, MD | Memorial Sloan Kettering Cancer Center |
| OverallOfficial: | Jonathan S. Berek, MD | Stanford Comprehensive Cancer Center - Palo Alto |
More Information
| ClinicalTrials.gov Identifier: | NCT00693342 History of Changes |
| Other Study ID Numbers: |
CDR0000597674 GOG-OVM0703 |
| Study First Received: | June 6, 2008 |
| Last Updated: | April 8, 2013 |
Keywords provided by Gynecologic Oncology Group:
|
stage IA primary peritoneal cavity cancer stage IB primary peritoneal cavity cancer stage IC primary peritoneal cavity cancer stage IIA primary peritoneal cavity cancer stage IIB primary peritoneal cavity cancer stage IIC primary peritoneal cavity cancer stage IIIA primary peritoneal cavity cancer stage IIIB primary peritoneal cavity cancer stage IIIC primary peritoneal cavity cancer stage IV primary peritoneal cavity cancer stage IA fallopian tube cancer stage IB fallopian tube cancer stage IC fallopian tube cancer stage IIA fallopian tube cancer stage IIB fallopian tube cancer |
stage IIC fallopian tube cancer stage IIIA fallopian tube cancer stage IIIB fallopian tube cancer stage IIIC fallopian tube cancer stage IV fallopian tube cancer stage IA ovarian epithelial cancer stage IB ovarian epithelial cancer stage IC ovarian epithelial cancer stage IIA ovarian epithelial cancer stage IIB ovarian epithelial cancer stage IIC ovarian epithelial cancer stage IIIA ovarian epithelial cancer stage IIIB ovarian epithelial cancer stage IIIC ovarian epithelial cancer stage IV ovarian epithelial cancer |
Additional relevant MeSH terms:
|
Fallopian Tube Neoplasms Peritoneal Neoplasms Genital Neoplasms, Female Urogenital Neoplasms Neoplasms by Site Neoplasms Fallopian Tube Diseases Adnexal Diseases Genital Diseases, Female |
Abdominal Neoplasms Digestive System Neoplasms Digestive System Diseases Peritoneal Diseases Vaccines Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on September 18, 2017